GILEAD SCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
GILEAD SCIENCES, INC. (GILD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $836.50 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2014-02-25
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2013 was $836.50M, a 67.30% increase from fiscal 2012.
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2012 was $500.00M, a 157.07% increase from fiscal 2011.
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2011 was $194.50M, a 25.85% decline from fiscal 2010.
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2010 was $262.30M, a 30.94% decline from fiscal 2009.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2013-12-31 | $836.50M 10-K · filed 2014-02-25 |
| 2012-12-31 | $500.00M 10-K · filed 2014-02-25 |
| 2011-12-31 | $194.50M 10-K · filed 2014-02-25 |
| 2010-12-31 | $262.30M 10-K · filed 2013-02-27 |
| 2009-12-31 | $379.80M 10-K · filed 2012-02-23 |
| 2008-12-31 | $551.70M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |